The chemotherapy drug doxorubicin encapsulated in nanoparticles an be especially effective in treating triple-negative breast cancer, according to a study published in Precision Nanomedicine.
Researchers found that increased cell kill in triple-negative breast cancer cells was associated with the smallest size of nanoparticles and the slowest release of doxorubicin.
“Nanomedicine is a very exciting avenue in modern drug development,” said Adam Friedman, MD, director of the Supportive Oncodermatology Clinic at GW Cancer Center, professor of dermatology at the George Washington School of Medicine and Health Sciences, and senior author of the study. “Nanotechnology offers many benefits, including the ability to purposefully customize your drug or diagnostic at the atomic scale, enhancing its ability to interact with its biological target and improve outcomes and potentially safety.”
Friedman acknowledges that this study is an initial step, but it “provides clues for new potential strategies utilizing and manipulating nanotechnology to overcome cancer cell drug resistance. We have our work cut out for us, but this study shows that we are moving in the right direction.”